Szczepionka przeciwko afrykańskiemu pomorowi świń

African swine fever (ASF), occurring for many years, is at present the most significant viral disease of swine and wild boar. Despite of the situation, defined as a large epidemic or even pandemic, a vaccine is not yet available, It has been claimed that live, attenuated anti-ASF vaccines are most promising products on the way to control the disease. However the safe and effective vaccine is yet to be obtained. The current status in the field of ASFV vaccine development is encouraging, since ASFV strain(s) have been obtained, that have their virulence genes deleted. Deletion of ASFV genes that inhibit host antiviral type I interferon responses is considered as the most effective strategy to attenuate the virus. Deleted, live vaccinal strain(s) are still able to replicate and encode immunogenic antigens thus induce protective immunity in swine. However, a licensed cell line in which live, attenuated virus (LAV) can be propagated and produced on a large scale, is still not available. Concerning wild boar, the natural reservoir of ASFV, while developing live vaccine for swine protection, rigorous conditions for its safety and efficacy are strongly required.